Pancreatic Cancer Research

ResearcherNational Hospital Organization Kyushu Cancer CenterActive in the last 2 years

Keishi Sugimachi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8768-5388; OpenAlex author ID A5057146510. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Symptom presentation at diagnosis as a biological risk indicator in both resectable and unresectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00595-026-03369-y↗
  2. Combined effect of frailty and sarcopenia on postoperative complications in older adults undergoing curative surgery for hepato-biliary-pancreatic cancer. First author DOI 10.1002/ags3.12897↗
  3. Pancreatic cancer secondary to biliary tract cancer associated with pancreaticobiliary maljunction: intraductal dissemination through the common channel. Co-author DOI 10.1007/s12328-025-02108-z↗
  4. Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12686↗
  5. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  6. Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348221086782↗
  7. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma. First author DOI 10.1371/journal.pone.0288033↗
  8. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  9. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  10. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Co-author DOI 10.1016/j.pan.2021.08.003↗
  11. Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.011↗
  12. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  13. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Co-author PMID 27127150↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masaru Morita · 5 shared papers, 2023–2026 · strength 1.10
  2. Tomonari Shimagaki · 4 shared papers, 2023–2025 · strength 0.83
  3. Takahiro Tomino · 3 shared papers, 2023–2026 · strength 0.67
  4. Shinji Itoh · 5 shared papers, 2016–2023 · strength 0.56
  5. Tomoharu Yoshizumi · 5 shared papers, 2016–2023 · strength 0.55
  6. Tomohiro Iguchi · 4 shared papers, 2020–2023 · strength 0.54
  7. Yasushi Toh · 2 shared papers, 2023 · strength 0.34
  8. Soichiro Morinaga · 3 shared papers, 2020–2022 · strength 0.34
  9. Mototsugu Shimokawa · 2 shared papers, 2023 · strength 0.31
  10. Norifumi Harimoto · 2 shared papers, 2016–2025 · strength 0.29
  11. Lingaku Lee · 1 shared paper, 2026 · strength 0.26
  12. Tohru Utsunomiya · 2 shared papers, 2021–2023 · strength 0.25
  13. Masayuki Furukawa · 1 shared paper, 2025 · strength 0.25
  14. Norihisa Takakura · 2 shared papers, 2020–2022 · strength 0.21
  15. Atsushi Miyamoto · 2 shared papers, 2020–2022 · strength 0.21
  16. Masafumi Ikeda · 2 shared papers, 2020–2022 · strength 0.21
  17. Shinichiro Takahashi · 2 shared papers, 2020–2022 · strength 0.21
  18. Motohiro Kojima · 2 shared papers, 2020–2022 · strength 0.21
  19. Katsuhiko Uesaka · 2 shared papers, 2020–2022 · strength 0.21
  20. Hirochika Toyama · 2 shared papers, 2020–2022 · strength 0.21
  21. Wataru Takayama · 2 shared papers, 2020–2022 · strength 0.21
  22. Masaki Mori · 2 shared papers, 2020–2021 · strength 0.20
  23. Norifumi Iseda · 1 shared paper, 2023 · strength 0.17
  24. Hiroshi Matsuura · 1 shared paper, 2023 · strength 0.17
  25. Hiromitsu Hayashi · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.